NME2 and acute myeloid leukemia: In our previous studies, we observed that polymorphisms in other genes encoding enzymes in the Ara-C metabolic pathway such as DCK, NME2 (DNPK-B), RRM2, and SAMHD1 are also associated drug response to Ara-C based therapies in AML [10, 16].